(S)-6-Chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one - CAS 154598-52-4
Catalog: |
BB011034 |
Product Name: |
(S)-6-Chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one |
CAS: |
154598-52-4 |
Synonyms: |
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one |
IUPAC Name: | (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one |
Description: | Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are highly specific and potent allosteric inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase. Efavirenz is an NNRTI that prevents RNA plus-strand initiation with an IC50 value of 17 nM. Efavirenz also inhibits the late stages of HIV-1 replication by interfering with HIV-1 Gag-Pol polyprotein processing. It has been used in combination therapy with drugs directed at the treatment of opportunistic infections such as HIV and cancer. |
Molecular Weight: | 315.67 |
Molecular Formula: | C14H9ClF3NO2 |
Canonical SMILES: | C1CC1C#CC2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F |
InChI: | InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1 |
InChI Key: | XPOQHMRABVBWPR-ZDUSSCGKSA-N |
Boiling Point: | 340.6 °C at 760 mmHg |
Melting Point: | 139-141°C |
Flash Point: | 209.4±31.5 °C |
Purity: | > 98 % |
Density: | 1.53 g/cm3 |
Solubility: | In Vitro: DMSO: ≥ 38 mg/mL (120.38 mM) |
Appearance: | White to off-white (Solid) |
Storage: | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
LogP: | 4.21110 |
Vapor Pressure: | 0.0±1.1 mmHg at 25°C |
GHS Hazard Statement: | H302 (51.72%): Harmful if swallowed [Warning Acute toxicity, oral] |
Precautionary Statement: | P201, P202, P260, P264, P270, P273, P280, P281, P301+P312, P305+P351+P338, P308+P313, P314, P330, P337+P313, P391, P405, and P501 |
Signal Word: | Danger |
Publication Number | Title | Priority Date |
CN-113288905-A | Pharmaceutical composition containing dortavir sodium, lamivudine and norfovir disoproxil fumarate | 20210714 |
CN-113350338-A | Pharmaceutical composition for resisting platelet aggregation and treating other diseases and application thereof | 20210709 |
CN-113456651-A | Stable pharmaceutical composition of tenofovir disoproxil fumarate | 20210630 |
CN-113416708-A | Immune cell expressing cytokine receptor fusion type chimeric antigen receptor and application thereof | 20210610 |
CN-113355458-A | Detection method and kit for inferior drug-resistant strains in HIV whole genome splicing and primary infected persons and application of detection method and kit | 20210608 |
PMID | Publication Date | Title | Journal |
34118364 | 20210801 | HAART exacerbates testicular damage and impaired spermatogenesis in anti-Koch-treated rats via dysregulation of lactate transport and glutathione content | Reproductive toxicology (Elmsford, N.Y.) |
33261845 | 20210101 | Computational drug discovery and repurposing for the treatment of COVID-19: A systematic review | Bioorganic chemistry |
33051194 | 20201013 | Discontinuation due to neuropsychiatric adverse events with efavirenz- and dolutegravir-based antiretroviral therapy: a comparative real-life study | European journal of hospital pharmacy : science and practice |
32235557 | 20200330 | Scaffold Hopping in Discovery of HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors: From CH(CN)-DABOs to CH(CN)-DAPYs | Molecules (Basel, Switzerland) |
31935327 | 20200213 | Discovery and Characterization of Fluorine-Substituted Diarylpyrimidine Derivatives as Novel HIV-1 NNRTIs with Highly Improved Resistance Profiles and Low Activity for the hERG Ion Channel | Journal of medicinal chemistry |
Complexity: | 519 |
Compound Is Canonicalized: | Yes |
Covalently-Bonded Unit Count: | 1 |
Defined Atom Stereocenter Count: | 1 |
Defined Bond Stereocenter Count: | 0 |
Exact Mass: | 315.0273907 |
Formal Charge: | 0 |
Heavy Atom Count: | 21 |
Hydrogen Bond Acceptor Count: | 5 |
Hydrogen Bond Donor Count: | 1 |
Isotope Atom Count: | 0 |
Monoisotopic Mass: | 315.0273907 |
Rotatable Bond Count: | 1 |
Topological Polar Surface Area: | 38.3 Å2 |
Undefined Atom Stereocenter Count: | 0 |
Undefined Bond Stereocenter Count: | 0 |
XLogP3: | 4 |
-
Catalog: BB002113
3-Phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-one
Detail
-
Catalog: BB076933
3-Oxo-3,4-dihydro-2H-benzo[b][1,4]oxazine-6-carbonitrile
Detail
-
Catalog: BB014289
6-Bromo-5-methyl-1H-benzo[d][1,3]oxazin-2(4H)-one
Detail
-
Catalog: BB040661
6-Methoxy-2,2-dimethyl-2H-benzo[b][1,4]oxazin-3(4H)-one
Detail
-
Catalog: BB054041
N-[2-(4-oxo-4H-3,1-benzoxazin-2-yl)phenyl]-2-naphthalenesulfonamide
Detail
-
Catalog: BB013387
8-Fluoro-1H-benzo[d][1,3]oxazin-2(4H)-one
Detail
-
Catalog: BB001093
7-Fluoro-2H-1,4-benzoxazin-3(4H)-one
Detail
-
Catalog: BB000972
6-Bromo-5-fluoro-2H-benzo[b][1,4]oxazin-3(4H)-one
Detail
Online Inquiry
Customer Support
Customer Centered
Related Functional Groups
Benzoxazines
-
[154598-52-4]
(S)-6-Chloro-4-(cyclopropylethynyl)-4-(trifluoromethyl)-1,4-dihydro-2H-benzo[d][1,3]oxazin-2-one
-
[107624-49-7]
3-Phenyl-3,4-dihydro-2H-1,4-benzoxazin-2-one
-
[627870-58-0]
6-Ethynyl-2H-benzo[b][1,4]oxazin-3(4H)-one
-
[688363-48-6]
8-Bromo-2H-1,4-benzoxazin-3(4H)-one
-
[441066-03-1]
1,3-Dihydro-1,3,3-trimethylspiro[2H-indole-2,3'-[3H]naphth[2,1-b][1,4]oxazine]-5-carboxylic acid
-
[1780525-17-8]
5-Fluoro-1H-benzo[d][1,3]oxazin-2(4H)-one
Customers Also Viewed
INDUSTRY LEADERS TRUST OUR PRODUCTS